Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with ...

There was a significant drop in the number of babies hospitalized with RSV this year; a positive news story that can be ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in ...